One possible explanation for the close relationship of this biomarker with treatment response could be that HLA-C*06:02 patients suffer from an endotype of psoriasis which is highly dependent on IL12/23 signaling that would make them more sensitive to the blockade of this pathway [53]. This evidence concerns the gene HLA-C and psoriasis.